The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...

Patients on anifrolumab spent more time in remission and low disease activity, and reached those states more quickly, vs. placebo. Achieving these states can stave off permanent organ damage.

Anifrolumab was all-but written off in 2018 after failing the phase 3 TULIP-1 trial, but bounced back with positive data from a second study – TULIP-2 – that has proved sufficient for the FDA ...

After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...

Zahi Touma, MD, PhD, from the University Health Network in Toronto, and colleagues examined whether anifrolumab plus SOC is associated with reduced organ damage accumulation compared with SOC only ...